Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Low-risk Early Triple-negative Breast Cancer
NCT06787339Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in triple negative breast cancer (TNBC), sponsored by Fudan University. Started Jan 2025; status: recruiting.
02
Drugs
capecitabine
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06787339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787339.